Prediction of response to neoadjuvant chemotherapy in patients with muscle-invasive urothelial bladder cancer: role of immune-related gene expression

Résumé

This prospective study aimed at investigating the role of immune-related gene expression (GATA3, METTL3, ERCC2, PD-L1 and IFN-γ) in the prediction of response to platinum-based neoadjuvant chemotherapy (NAC) in treatment of muscle-invasive bladder cancer (MIBC). A total of 112 patients received four cycles of systemic cisplatin-based NAC and then were subjected to radiological and histopathological evaluation through taking bladder biopsy before surgery. Quantitative real-time RT-PCR assessed GATA3, METTL3 and ERCC2 mRNA expression in tissue samples. Immunohistochemical (IHC) staining was done for GATA3, PD-L1 and IFN-γ in tissue samples. Out of the 112 patients, only 104 completed the proposed protocol of systemic NAC and were included in the final analysis. Out of 104 patients, 43 (41.4%) were responders and the remaining 61 patients (58.6%) were assigned as non-responders. GATA3 and IFN-γ expressions were significantly higher in tumor tissue of the responders compared to non-responders. METTL3 and ERCC2 expressions were significantly lower in tumor tissue of the responders compared to non-responders, whereas, PD-L1 staining showed no significant difference between both groups. Our study suggests that GATA3, METTL3, ERCC2, and IFN-γ could serve as predictive biomarkers for NAC response in MIBC patients. Higher GATA3 and IFN-γ along with lower METTL3 and ERCC2 levels are positively correlated with better response to NAC.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0